- Conference Call and Webcast to Follow at 5:00 p.m. EDT/ 2:00 p.m.
PDT -
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jul. 28, 2015--
Exelixis, Inc. (NASDAQ: EXEL) announced today that its second quarter
2015 financial results will be released on Tuesday, August 11, 2015
after the markets close. At 5:00 p.m. EDT / 2:00 p.m. PDT, Exelixis
management will host a conference call to discuss the results and
provide a general business update. The conference call will be
accessible via the Internet from the company’s website.
To access the webcast link, log onto www.exelixis.com
and proceed to the Event Calendar page under Investors & Media. Please
connect to the company’s website at least 15 minutes prior to the
conference call to ensure adequate time for any software download that
may be required to listen to the webcast. Alternatively, please call
855-793-2457 (domestic) or 631-485-4921 (international) and provide the
conference call passcode 94776699 to join by phone.
A telephone replay will be available until 11:59 p.m. EDT on August 13,
2015. Access numbers for the telephone replay are: 855-859-2056
(domestic) and 404-537-3406 (international); the passcode is 94776699. A
webcast replay will also be archived on www.exelixis.com
for one year.
About Exelixis
Exelixis, Inc. is a biopharmaceutical company committed to developing
small molecule therapies for the treatment of cancer. Exelixis is
focusing its development and commercialization efforts primarily on
COMETRIQ® (cabozantinib), its wholly-owned inhibitor of multiple
receptor tyrosine kinases. Another Exelixis-discovered compound,
cobimetinib, a selective inhibitor of MEK, is being evaluated by Roche
and Genentech, Inc. (a member of the Roche Group) in a broad development
program under a collaboration with Exelixis. For more information,
please visit the company's web site at www.exelixis.com.
Exelixis, the Exelixis logo, and COMETRIQ are registered U.S.
trademarks.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150728006806/en/
Source: Exelixis, Inc.
Exelixis, Inc.
Susan Hubbard, 650-837-8194
Investor
Relations and Corporate Communications
shubbard@exelixis.com
